Cargando…

Efficacy of Serotherapy on an N501Y Variant of SARS-CoV-2 in a Patient With Chronic Lymphocytic Leukemia

Detalles Bibliográficos
Autores principales:	Vercueil, Colin, Eberst, Lauriane, Humbrecht, Catherine, Fornecker, Luc-Matthieu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647882/ https://www.ncbi.nlm.nih.gov/pubmed/34881357 http://dx.doi.org/10.1097/HS9.0000000000000655

Ejemplares similares

Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity
por: Tang, Haijun, et al.
Publicado: (2021)

Corrigendum: Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity
por: Tang, Haijun, et al.
Publicado: (2021)

SARS-CoV-2 N501Y variants of concern and their potential transmission by mouse
por: Huang, Hongyan, et al.
Publicado: (2021)

Serotherapy of a spontaneous mouse tumour.
por: O'Neill, G. J.
Publicado: (1980)

Paths to the discovery of antivenom serotherapy in France
por: Bochner, Rosany
Publicado: (2016)

Potential and challenges of serotherapy for severe influenza
por: Lee, Nelson, et al.
Publicado: (2017)

Antigangrenous Serotherapy by a Multivalent Serum
Publicado: (1918)

INTRAVENOUS SEROTHERAPY OF WEIL'S DISEASE (SPIROCHÆETOSIS ICTEROHÆMORRHAGICA)
por: Inada, Ryokichi, et al.
Publicado: (1918)

Tolerance to rat monoclonal antibodies. Implications for serotherapy
Publicado: (1986)

Quand les Français redécouvrent la sérothérapie
por: Manus, Jean-Marie
Publicado: (2020)

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro
por: Liu, Haolin, et al.
Publicado: (2021)

In silico analysis of SARS-CoV-2 spike protein N501Y and N501T mutation effects on human ACE2 binding
por: Çubuk, Hasan, et al.
Publicado: (2022)

Emil Behring's Medical Culture: From Disinfection to Serotherapy
por: SIMON, JONATHAN
Publicado: (2007)

110 Broadly neutralizing antibodies for serotherapy and vaccine design
por: Lanzavecchia, Antonio
Publicado: (2014)

A novel single nucleotide polymorphism assay for the detection of N501Y SARS-CoV-2 variants
por: Sandoval Torrientes, M., et al.
Publicado: (2021)

Clinical Characteristics of Patients with SARS-CoV-2 N501Y Variants in General Practitioner Clinic in Japan
por: Hanafusa, Mariko, et al.
Publicado: (2021)

Spreading of a new SARS-CoV-2 N501Y spike variant in a new lineage
por: Colson, Philippe, et al.
Publicado: (2021)

Detection of SARS-CoV-2 N501Y mutation among SARS-CoV-2 variants of concern circulating in Northern Cyprus
por: Tuncel, Gulten, et al.
Publicado: (2022)

Decreased glycolipid antigen expression in lymphoma cell variants escaping from anti-glycolipid serotherapy
Publicado: (1983)

The N501Y spike substitution enhances SARS-CoV-2 transmission
por: Liu, Yang, et al.
Publicado: (2021)

The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages
por: Martin, Darren P., et al.
Publicado: (2021)

Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
por: Pymm, Phillip, et al.
Publicado: (2021)

A modified high-resolution melting-based assay (HRM) to identify the SARS-CoV-2 N501Y variant
por: Aoki, Akira, et al.
Publicado: (2023)

Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets
por: Riddell, Shane, et al.
Publicado: (2021)

The basis of a more contagious 501Y.V1 variant of SARS-CoV-2
por: Liu, Haolin, et al.
Publicado: (2021)

Thermodynamics and kinetics in antibody resistance of the 501Y.V2 SARS-CoV-2 variant
por: Ngo, Son Tung, et al.
Publicado: (2021)

Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK
por: Tang, Julian W., et al.
Publicado: (2021)

Dynamics of SARS-CoV-2 mutations reveals regional-specificity and similar trends of N501 and high-frequency mutation N501Y in different levels of control measures
por: Justo Arevalo, Santiago, et al.
Publicado: (2021)

Immunity evasion: consequence of the N501Y mutation of the SARS-CoV-2 spike glycoprotein
por: Uzoeto, Henrietta Onyinye, et al.
Publicado: (2022)

Implementation of an in-house real-time reverse transcription-PCR assay to detect the emerging SARS-CoV-2 N501Y variants
por: Bedotto, Marielle, et al.
Publicado: (2021)

A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations
por: Zhao, Yanan, et al.
Publicado: (2021)

The SARS-CoV-2 Delta (B.1.617.2) variant with spike N501Y mutation in the shadow of Omicron emergence
por: Salimović-Bešić, Irma, et al.
Publicado: (2022)

Detection of SARS-CoV-2 variant 501Y.V2 in Comoros Islands in January 2021
por: N. Agoti, Charles, et al.
Publicado: (2021)

Preliminary data on severe SARS-CoV-2 infection caused by the 501Y.V2 variant
por: Louis, Guillaume, et al.
Publicado: (2021)

Les venins, les animaux venimeux et la serotherapie anti-venimeuse
Publicado: (1907)

SARS-CoV2 spike protein gene variants with N501T and G142D mutation–dominated infections in mink in the United States
por: Cai, Hugh Y., et al.
Publicado: (2021)

A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue
por: Puligedda, Rama Devudu, et al.
Publicado: (2021)

Replacement of SARS-CoV-2 strains with variants carrying N501Y and L452R mutations in Japan: an epidemiological surveillance assessment
por: Kobayashi, Yusuke, et al.
Publicado: (2022)

First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 2020
por: Fiorentini, Simona, et al.
Publicado: (2021)

The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients
por: Teyssou, Elisa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hivvejjqfsj7kln8jnklqd70m9